HomeREGULATORY
REGULATORY

Keytruda’s Sakigake Designation Revoked after Opdivo Gastric Cancer Nod
(Sep.29.2017)

A health ministry panel on September 28 approved the withdrawal of a sakigake fast-track designation for MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) as a gastric cancer treatment after its archrival in the class, Opdivo (nivolumab), earned the nod for the indication ...
(LOG IN FOR FULL STORY)

News Calendar